MediTrust Health and Sino Biopharm Partner to Advance Drug-Insurance Integration

At the 8th China International Import Expo (CIIE 2025), Sino Biopharmaceutical Limited and Shanghai MediTrust Health Technology Group signed a strategic cooperation agreement. The partnership will focus on innovative drugs and commercial insurance, jointly exploring a new model of drug-insurance integration to enable earlier patient access to high-quality, affordable medicines.

Promoting Sustainable Healthcare Solutions

Mr. Tse Hsin, Executive Director of Sino Biopharm, highlighted that the company generates annual revenue of approximately RMB 30 billion, ranks 38th among the Top 50 Global Pharmaceutical Companies, and has a pipeline of over 120 innovative drugs. He emphasized that integrating commercial insurance with innovative therapies helps alleviate pressure on public medical funds, supports R&D investment, and promotes a sustainable pharmaceutical ecosystem.

Collaboration to Transform Patient Access

The partnership will leverage commercial insurance channels to accelerate patient access to innovative medicines, enhance affordability, and foster a patient-centric healthcare model. Both companies aim to create a replicable framework for drug-insurance integration, aligning with China’s ongoing healthcare reforms and evolving market needs.